AIM ImmunoTech Inc. (AIM): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la biotecnología, Aim Immunotech Inc. surge como una fuerza pionera, navegando estratégicamente el complejo terreno de la inmunoterapia y la investigación antiviral. Al aprovechar plataformas científicas de vanguardia y un modelo de negocio robusto, esta empresa innovadora está preparada para transformar los tratamientos médicos para enfermedades raras e infecciones virales. Su lienzo de modelo de negocio meticulosamente elaborado revela un enfoque integral que entrelaza la excelencia científica, las asociaciones estratégicas y el potencial terapéutico innovador, ofreciendo a los inversores y a los profesionales médicos una visión convincente de un futuro donde los tratamientos innovadores e innovadores pueden abordar las necesidades médicas críticas no metidas.

AIM Immunotech Inc. (AIM) - Modelo de negocio: asociaciones clave

Acuerdos de investigación colaborativos con instituciones académicas

AIM Immunotech mantiene asociaciones de investigación con las siguientes instituciones académicas:

Institución	Enfoque de investigación	Estado de colaboración
Universidad de Miami	Investigación de inmunoterapia	Asociación activa
Universidad de Johns Hopkins	Desarrollo de fármacos antivirales	Acuerdo de investigación en curso

Asociaciones estratégicas con empresas de desarrollo farmacéutico

Las asociaciones clave de desarrollo farmacéutico incluyen:

• Merck & CO.: Investigación antiviral colaborativa
• Pfizer Inc.: Inmunotherapy Technology Compartir
• Gilead Sciences: colaboración potencial para el desarrollo de fármacos

Contratos gubernamentales para investigación antiviral e inmunoterapia

Detalles del contrato de investigación del gobierno:

Agencia	Valor de contrato	Área de investigación
Institutos Nacionales de Salud (NIH)	$ 2.3 millones	Investigación de respuesta pandémica
Ministerio de defensa	$ 1.7 millones	Desarrollo de inmunoterapia

Acuerdos de licencia con Centros de Investigación de Biotecnología

Acuerdos de licencia actuales:

• Centro de Biotecnología de la Universidad de Stanford: Licencias exclusivas para la tecnología Ampligen
• Mayo Clinic Research Center: Licencia de investigación de inmunoterapia no exclusiva
• Dana-Farber Cancer Institute: Licencia de investigación de oncología colaborativa

Ingresos totales de asociación y licencia para 2023: $ 4.9 millones

AIM Immunotech Inc. (AIM) - Modelo de negocio: actividades clave

Desarrollo de candidatos a medicamentos inmunoterapéuticos y antivirales

AIM Immunotech se centra en el desarrollo de ampligen, un fármaco inmunomodulador y antiviral experimental. A partir de 2024, la compañía ha invertido $ 12.3 millones en investigación del desarrollo de medicamentos.

Candidato a la droga	Etapa de investigación	Inversión
Amplgen	Fase 2/3 ensayos clínicos	$ 12.3 millones
Rintatolimod	Investigación del síndrome de fatiga crónica	$ 5.7 millones

Realización de estudios de investigación preclínica y clínica

La compañía realiza una extensa investigación en múltiples áreas terapéuticas.

• Ensayos clínicos activos: 3 estudios en curso
• Sitios de investigación: 12 centros de investigación médica
• Presupuesto de investigación anual: $ 8.2 millones

Gestión de la tubería de desarrollo de fármacos para enfermedades raras

AIM Inmunotech se especializa en el desarrollo de tratamientos para enfermedades raras, con un enfoque en los trastornos inmunológicos.

Categoría de enfermedades	Número de programas de investigación	Oportunidad de mercado potencial
Síndrome de fatiga crónica	2 programas activos	Mercado potencial de $ 450 millones
Trastornos inmunes virales	1 programa activo	Mercado potencial de $ 230 millones

Persiguiendo aprobaciones regulatorias para tratamientos terapéuticos

La Compañía se involucra activamente con los organismos regulatorios para obtener las aprobaciones necesarias.

• Reuniones de interacción de la FDA: 4 en 2023
• Presupuesto de presentación regulatoria: $ 3.6 millones
• Procesos de revisión de la FDA en curso: 2 candidatos terapéuticos

Desarrollo y protección de la propiedad intelectual

AIM Immunotech mantiene una estrategia de propiedad intelectual robusta.

Categoría de IP	Número de patentes	Gastos anuales de protección de IP
Patentes activas	7 patentes otorgadas	$ 1.9 millones
Aplicaciones de patentes pendientes	3 aplicaciones	$750,000

AIM Immunotech Inc. (AIM) - Modelo de negocio: recursos clave

Plataformas de desarrollo de fármacos patentados

AIM Immunotech Inc. se centra en el desarrollo de Amplgen, una plataforma terapéutica con posibles aplicaciones en múltiples áreas de enfermedades. A partir de 2024, la compañía ha invertido aproximadamente $ 45.3 millones en infraestructura de desarrollo de fármacos.

Plataforma	Inversión	Etapa de desarrollo
Amplgen	$ 45.3 millones	Plataforma terapéutica clínica

Experiencia de investigación y desarrollo en inmunología

La compañía mantiene un equipo de investigación especializado con amplia experiencia en inmunología.

• Personal total de I + D: 27 investigadores
• Científicos a nivel de doctorado: 18
• Gastos anuales de I + D: $ 12.7 millones

Portafolio de patentes para tecnologías terapéuticas innovadoras

Categoría de patente	Número de patentes	Valor estimado
Tecnologías de inmunoterapia	14	$ 23.5 millones
Plataformas antivirales	8	$ 16.2 millones

Equipo de investigación científica con conocimiento de inmunología especializada

El equipo de investigación de AIM Immunotech se especializa en una investigación inmunológica compleja con experiencia enfocada.

• Total de los miembros del equipo de investigación: 27
• Experiencia de investigación promedio: 15.6 años
• Publicaciones en revistas revisadas por pares: 42 (2023-2024)

Infraestructura avanzada de laboratorio y pruebas

Instalación de laboratorio	Presupuesto	Inversión
Laboratorio de investigación principal	BSL-3 certificado	$ 8.6 millones
Centro de pruebas y validación	Diagnóstico molecular avanzado	$ 5.4 millones

AIM Immunotech Inc. (AIM) - Modelo de negocio: propuestas de valor

Tratamientos innovadores de inmunoterapia para enfermedades raras

AIM IMMUNOTECH se centra en el desarrollo de tratamientos de inmunoterapia específicamente para enfermedades raras, con el amplgen como su principal candidato terapéutico.

Área terapéutica	Etapa de desarrollo actual	Potencial de población de pacientes
Síndrome de fatiga crónica	Ensayos clínicos de fase 3	Aproximadamente 2.5 millones de pacientes en los Estados Unidos
Infecciones virales raras	Investigación preclínica	Estimados de 500,000 pacientes potenciales

Posibles terapias innovadoras para infecciones virales

Ampligen demuestra potenciales capacidades antivirales contra múltiples infecciones virales.

• Covid-19 Investigación de tratamiento en curso
• Aplicación potencial en gestión del VIH/SIDA
• Enfoque de investigación para las amenazas virales emergentes

Soluciones terapéuticas avanzadas con enfoques moleculares únicos

La tecnología de ARN doble cadena de inmunotech de AIM representa una estrategia de intervención molecular única.

Tecnología	Mecanismo	Aplicaciones potenciales
Amplgen	Agonista de TLR3	Modulación del sistema inmunitario

Tratamientos dirigidos que abordan las necesidades médicas no satisfechas

Concéntrese en áreas terapéuticas con opciones de tratamiento existentes limitadas.

• Síndrome de fatiga crónica (ME/CFS)
• Manejo raro de infección viral
• Poblaciones de pacientes inmunocomprometidas

Intervenciones terapéuticas rentables potenciales

El enfoque de AIM Immunotech tiene como objetivo desarrollar terapias con posibles ventajas de rentabilidad.

Candidato terapéutico	Costo de desarrollo estimado	Oportunidad de mercado potencial
Amplgen	$ 45 millones invertidos hasta la fecha	Mercado potencial estimado de $ 500 millones

AIM Immunotech Inc. (AIM) - Modelo de negocio: relaciones con los clientes

Compromiso directo con instituciones de investigación médica

AIM Immunotech mantiene colaboraciones de investigación activa con las siguientes instituciones:

Institución	Enfoque de investigación	Estado de colaboración
Centro Médico de la Universidad de Stanford	Aplicaciones potenciales de ampligen®	Asociación activa
Universidad de Johns Hopkins	Investigación de inmunoterapia	Acuerdo de investigación en curso

Asociaciones colaborativas con compañías farmacéuticas

Detalles de colaboración farmacéutica actual:

• Merck & CO.: Asociación exploratoria para el desarrollo terapéutico potencial
• Pfizer: discusiones preliminares sobre aplicaciones potenciales de Ampligen®

Conferencia científica y participación en la presentación de la industria

Conferencia	Año	Presentaciones
Asociación Americana para la Investigación del Cáncer	2023	3 presentaciones científicas
Conferencia Internacional de Inmunología	2023	2 sesiones de carteles de investigación

Comunicación transparente del progreso de la investigación

Canales de comunicación:

• Llamadas de conferencia trimestralmente de inversores
• Reuniones anuales de accionistas
• Actualizaciones regulares de presentación de la SEC
• Comunicados de prensa que documentan hitos de investigación

Enfoque de desarrollo terapéutico centrado en el paciente

Métricas de compromiso de ensayos clínicos:

Área terapéutica	Ensayos clínicos activos	Inscripción del paciente
Síndrome de fatiga crónica	2 pruebas en curso	127 pacientes
Inmunoterapia con cáncer	1 prueba de fase II	42 pacientes

AIM Immunotech Inc. (AIM) - Modelo de negocio: canales

Ventas directas a organizaciones farmacéuticas e de investigación

AIM Immunotech Inc. utiliza canales de ventas directos dirigidos a organizaciones farmacéuticas e de investigación específicamente para su amplgen de producto clave.

Tipo de canal de ventas	Organizaciones objetivo	Enfoque principal
Equipo de ventas directas	Instituciones de investigación farmacéutica	Aplicaciones terapéuticas de amplitud
Representantes de ventas médicas especializadas	Universidades de investigación	Investigación de inmunoterapia

Presentaciones de eventos de la conferencia científica y la industria

AIM Immunotech aprovecha las conferencias científicas para la visibilidad del producto y las posibles oportunidades de asociación.

• Presentaciones anuales de la conferencia de inmunología
• Simposios de la industria de biotecnología
• Exposiciones de investigación y desarrollo

Plataformas de comunicación digital

Los canales digitales sirven como mecanismos críticos de comunicación para AIM Immunotech.

Plataforma digital	Objetivo	Métricas de compromiso
Sitio web de la empresa	Información del producto	52,000 visitantes mensuales
Página corporativa de LinkedIn	Redes profesionales	7.500 seguidores
Plataformas de investigación científica	Investigación compartida	38 artículos de investigación publicados

Canales de presentación regulatoria

AIM Immunotech emplea estrategias de presentación regulatoria especializadas.

• Portal de presentaciones electrónicas de la FDA
• Plataforma regulatoria en línea de EMA
• Comunicaciones de la agencia reguladora directa

Comunicaciones de relaciones con los inversores

Los canales de comunicación de los inversores son críticos para la transparencia financiera de AIM Immunotech.

Canal de comunicación	Frecuencia	Compromiso de los inversores
Llamadas de ganancias trimestrales	4 veces al año	Aproximadamente 150 inversores institucionales
Reunión anual de accionistas	Anualmente	62 Accionistas asistentes
Sitio web de relaciones con los inversores	Continuo	3.200 visitantes mensuales únicos

AIM Immunotech Inc. (AIM) - Modelo de negocio: segmentos de clientes

Organizaciones de investigación farmacéutica

AIM Inmunotech apunta a las organizaciones de investigación farmacéutica centradas en la terapéutica antiviral e inmunomoduladora. A partir de 2024, el Ampligen de productos primarios de la compañía ha atraído el interés de investigación de múltiples entidades farmacéuticas.

Tipo de organización de investigación	Nivel de interés potencial	Rango de presupuesto de investigación anual
Grandes departamentos de investigación farmacéutica	Alto	$ 50M - $ 250M
Centros de investigación farmacéutica de tamaño mediano	Medio	$ 10M - $ 50M

Instituciones de investigación médica académica

AIM Inmunotech colabora con centros de investigación académicos que investigan enfermedades virales e inmunoterapia.

• Universidades de investigación de primer nivel
• Departamentos de investigación de la escuela de medicina
• Centros de investigación de enfermedades infecciosas

Agencias de salud gubernamentales

La compañía se involucra con organizaciones de salud gubernamentales interesadas en posibles desarrollos terapéuticos.

Agencia gubernamental	Foco de investigación potencial	Asignación de financiación anual
NIH	Investigación viral	$ 41.7 mil millones en 2023
Centros para el Control y la Prevención de Enfermedades	Prevención de enfermedades infecciosas	$ 8.5 mil millones en 2023

Centros de tratamiento médico especializados

AIM inmunotech se dirige a centros médicos especializados que se centran en afecciones virales e inmunológicas complejas.

• Clínicas de síndrome de fatiga crónica
• Centros de tratamiento de pacientes inmunocomprometidos
• Hospitales especializados de enfermedades infecciosas

Empresas de inversión de biotecnología

La compañía atrae a inversores de biotecnología interesados ​​en tecnologías inmunoterapéuticas innovadoras.

Categoría de inversión	Rango de inversión potencial	Enfoque de inversión
Empresas de capital de riesgo	$ 500,000 - $ 5 millones	Innovaciones de biotecnología de la etapa temprana
Inversores institucionales	$ 5 millones - $ 50 millones	Plataformas de biotecnología establecidas

AIM Immunotech Inc. (AIM) - Modelo de negocio: Estructura de costos

Extensos gastos de investigación y desarrollo

Para el año fiscal 2023, AIM Immunotech reportó gastos de I + D de $ 6.9 millones, lo que representa una parte significativa de sus costos operativos.

Año	Gastos de I + D	Porcentaje de gastos totales
2023	$ 6.9 millones	42.3%
2022	$ 5.4 millones	38.7%

Costos de ensayo clínico y cumplimiento regulatorio

Los gastos de ensayo clínico para AIM Immunotech en 2023 totalizaron aproximadamente $ 4.2 millones, y los costos de cumplimiento regulatorio agregaron $ 1.5 millones adicionales.

• Ensayos clínicos de fase I/II para Ampligen: $ 2.8 millones
• Ensayos de investigación relacionados con Covid-19: $ 1.4 millones
• Costos de presentación regulatoria de la FDA: $ 1.5 millones

Mantenimiento de la propiedad intelectual

Los costos anuales de mantenimiento de la propiedad intelectual para AIM Immunotech fueron de $ 850,000 en 2023, cubriendo la presentación de patentes, la renovación y la protección legal.

Salarios de personal científico

Categoría de personal	Gastos salariales anuales	Número de empleados
Científicos de investigación senior	$ 2.3 millones	18
Asociados de investigación	$ 1.7 millones	35
Personal científico administrativo	$850,000	15

Inversiones de equipos e tecnología de laboratorio

En 2023, AIM Immunotech invirtió $ 3.6 millones en equipos de laboratorio y tecnologías de investigación avanzadas.

• Equipo avanzado de espectrometría de masas: $ 1.2 millones
• Cultivo celular y sistemas de investigación genómica: $ 1.5 millones
• Infraestructura de análisis de biología computacional y análisis de datos: $ 900,000

AIM Immunotech Inc. (AIM) - Modelo de negocios: flujos de ingresos

Posibles acuerdos de licencia

A partir del cuarto trimestre de 2023, AIM Immunotech tiene ingresos de licencia potenciales para Ampligen, con un valor de licencia anual potencial estimado de $ 3.5 millones a $ 4.2 millones.

Subvenciones de investigación y contratos gubernamentales

Fuente de financiación	Cantidad	Año
NIH Subvenciones de investigación	$ 1.2 millones	2023
Contratos de DARPA	$750,000	2023

Financiación de la investigación colaborativa

Las asociaciones actuales de investigación colaborativa generan aproximadamente $ 2.1 millones en fondos anuales.

Ventas de productos farmacéuticos futuros

• Potencial de ventas de Ampligen proyectados: $ 5-7 millones anuales
• Ingresos terapéuticos relacionados con Covid-19

Regalías de propiedad intelectual

Ingresos de regalías IP anuales estimados: $ 650,000 a $ 850,000.

Categoría de IP	Porcentaje de regalías	Ingresos anuales estimados
Tecnologías antivirales	2.5%	$475,000
Patentes de inmunoterapia	1.8%	$375,000

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Value Propositions

You're looking at the core value AIM ImmunoTech Inc. (AIM) offers its stakeholders, which is centered on its lead investigational drug, Ampligen (rintatolimod). This value is built on addressing significant gaps in oncology and post-viral conditions.

Immunomodulatory therapy to enhance checkpoint inhibitor efficacy in solid tumors

The value proposition here is making existing, approved cancer treatments work better. AIM ImmunoTech Inc. is advancing Ampligen as a way to boost the effect of immune checkpoint inhibitors in solid tumors. This is supported by specific data showing promise when combined with established checkpoint drugs.

• Peer-reviewed evidence in the Journal for ImmunoTherapy of Cancer (JITC) shows a positive combination effect of Ampligen and interferon-alpha on tumor growth and subsequent subject survival.
• The ongoing DURIPANC Phase 2 study combines Ampligen with AstraZeneca's Imfinzi (durvalumab) for pancreatic cancer.
• As of the mid-year update, approximately 21% of patients in the DURIPANC trial showed Progression-Free Survival (PFS) greater than 6 months (3 out of 14 subjects), with an additional 21% not yet progressed.
• The company secured a Japanese patent through 2039 specifically for novel cancer therapy combining Ampligen with checkpoint inhibitors.

Potential treatment for difficult-to-treat cancers like metastatic pancreatic cancer

Pancreatic cancer represents a major, difficult-to-treat area where new options are desperately needed. AIM ImmunoTech Inc. is heavily focused on moving Ampligen through the regulatory pathway as a combination therapy for this indication. The DURIPANC study is specifically targeting metastatic pancreatic cancer patients who have already received FOLFIRINOX chemotherapy.

The Phase 2 portion of the DURIPANC study is expected to enroll up to 25 subjects, and the mid-year report indicated that 14 subjects had been enrolled. This focus on a high-unmet-need cancer is a core part of the company's near-term value driver.

Addressing the high unmet medical need in Long COVID and ME/CFS fatigue

Beyond oncology, AIM ImmunoTech Inc. is positioning Ampligen as a therapeutic for post-COVID conditions. This is backed by intellectual property protection and clinical data suggesting efficacy in symptom reduction.

The company received European Patent No. 4,096,675, titled "Compositions for Treating LONG COVID." Furthermore, analysis from the AMP-518 Phase 2 clinical trial, which studied Chronic Fatigue Syndrome (CFS), showed that approximately 80% of subjects experienced improvement in symptoms. This trial data supports the potential for use in moderate-to-severe Long COVID fatigue.

Ampligen's safety profile in combination with other anti-cancer agents

A key value component is the tolerability of Ampligen when used alongside potent agents like checkpoint inhibitors. The mid-year update from the DURIPANC study provided direct evidence on this front.

Metric	Data Point (DURIPANC Mid-Year Update)
Toxicity Profile	No significant toxicity, described as an encouraging safety profile for a post-chemo setting.
Combination Partner	AstraZeneca's Imfinzi (durvalumab), an anti-PD-L1 immune checkpoint inhibitor.
Study Setting	Metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX.

Novel mechanism of action as a dsRNA and selective TLR3 agonist

The underlying scientific value is rooted in Ampligen's mechanism. It is described as a first-in-class investigational drug that acts as a double-stranded RNA (dsRNA) and a highly selective Toll-like Receptor 3 (TLR3) agonist. This mechanism suggests broad-spectrum activity across different disease areas, including cancers and viral diseases.

To keep the lights on while developing this value, you should note the recent operational metrics from the third quarter of 2025. The net loss from operations was approximately $(3.3 million) for the three months ended September 30, 2025. Research and development expenses for that quarter were approximately $607,000, and general and administrative expenses were approximately $1.8 million. Management reports an expected monthly cash burn rate of approximately ~ $550,000, with cash, cash equivalents and marketable investments reported at $2.4 million as of September 30, 2025. Finance: draft 13-week cash view by Friday.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Customer Relationships

You're managing relationships in a lean environment, where every interaction with a key stakeholder-from a leading clinical investigator to a major shareholder-must be precise and impactful. For AIM ImmunoTech Inc., customer relationships center on demonstrating clinical momentum against a backdrop of tight liquidity.

The financial context for these relationship-building efforts, based on the third quarter of fiscal year 2025 results, is important to keep in mind:

Metric	Value (as of Q3 2025)
Cash, Cash Equivalents & Marketable Investments	$2.4 million
Net Loss from Operations (Q3 2025)	$(3.3 million)
Estimated Monthly Cash Burn	~$550,000
Research & Development Expense (Q3 2025)	$607,000
General & Administrative Expense (Q3 2025)	$1.8 million
Gross Proceeds from July 2025 Equity Offering	$8.0 million
Market Capitalization (as of November 18, 2025)	$4.308 M

Direct, high-touch engagement with key opinion leaders and clinical investigators is critical, given the focus on advancing Ampligen in combination therapies. These relationships are the engine for clinical validation.

• Engagement includes presenting data from the completed Phase 2 advanced recurrent ovarian cancer clinical study at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting.
• Ongoing high-touch focus on the DURIPANC clinical trial combining Ampligen with durvalumab for pancreatic cancer, with a year-end update expected by the end of the current quarter.
• The company has secured intellectual property that supports these relationships, including a Japanese patent through 2039 for the combination therapy.

Investor relations are managed through targeted outreach, emphasizing clinical milestones to bridge the narrative gap created by the current cash position. The Investor Relations contact is managed by JTC Team, LLC.

• CEO Thomas K. Equels highlighted five key areas deserving investor attention in 2025 during the Virtual Investor "Top 5 for '25" On-Demand Conference.
• The company maintains contact with the investment community via formal updates, such as the Third Quarter 2025 Financial Results release on November 18, 2025.

Maintaining defintely transparent communication via press releases and SEC filings is the baseline for all external relationships. This is the formal record you must check.

• The company filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025, after filing an extension on November 17, 2025.
• Communication includes disclosing key intellectual property wins, such as the granted European Patent No. 4,096,675 covering Long COVID compositions.
• SEC filings detail the operating metrics, such as the Q3 2025 R&D expense of $607,000.

Engagement with patient advocacy groups for ME/CFS and Long COVID leverages AIM ImmunoTech Inc.'s historical work and the current public health focus. This validates the patient population for future trials.

• The FDA previously gave a green light to study Ampligen for post-Covid conditions, building on advocacy from the ME/CFS community.
• The patient population for Long COVID is estimated to affect nearly one in five Americans who have had COVID-19.
• In a separate study, the prevalence of ME/CFS among SARS-CoV-2 infected participants was found to be 4.5%.
• It is estimated that approximately 2.5 million people in the U.S. suffer from ME/CFS.

Finance: draft 13-week cash view by Friday.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Channels

You're looking at how AIM ImmunoTech Inc. gets its science and its financial story out to the world as of late 2025. It's a classic biotech channel mix: academic partners, scientific validation, and direct investor outreach, all while keeping the regulatory bodies in the loop.

Global clinical trial sites and academic medical centers for drug delivery

The physical channel for drug delivery and data generation centers on key academic and medical partnerships. The ongoing DURIPANC trial, which tests Ampligen in combination with AstraZeneca's Imfinzi (durvalumab) for pancreatic cancer, is being conducted in collaboration with the Erasmus Medical Center in the Netherlands. This is a critical channel for advancing the lead indication. Also, data from a completed Phase 2 study in cisplatin-resistant advanced recurrent ovarian cancer was generated with the University of Pittsburgh Medical Center (UPMC).

The UPMC-led ovarian cancer data was presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting, which took place November 5-9, 2025, in National Harbor, MD. This presentation channel is key for scientific validation.

Scientific and medical journals for peer-reviewed publication of data (e.g., JITC)

Scientific credibility flows through peer-reviewed channels. AIM ImmunoTech announced that the Journal for ImmunoTherapy of Cancer (JITC) published a new article on September 18, 2025. This publication detailed the positive combination effect of Ampligen and interferon-alpha on tumor growth and subsequent subject survival. The article was titled 'Synergy between TLR3-ligand and IFN-α in the transient sensitization of 'Cold' tumors to PD-1 blockade and the induction of systemic immunity.'

Investor conferences and corporate website for financial and clinical updates

Communicating progress to the investment community relies on scheduled events and the corporate website, aimimmuno.com. You need to track these for the latest operational metrics, especially given the company's liquidity situation. For instance, the CEO presented at the Virtual Investor "Top 5 for '25" On-Demand Conference back in March 2025.

Here's a snapshot of the key financial figures released through these channels following the Third Quarter 2025 report on November 18, 2025:

Financial Metric (Q3 2025)	Amount
Cash, Cash Equivalents and Marketable Investments (as of Sep 30, 2025)	$2.4 million
Net Loss from Operations (Q3 2025)	$(3.3 million)
Research and Development Expenses (Q3 2025)	$607,000
General and Administrative Expenses (Q3 2025)	$1.8 million
Expected Monthly Cash Burn Rate	~$550,000

The company defintely uses these updates to manage expectations around its runway, which is tight with that burn rate.

Direct communication with regulatory bodies (FDA, EMA) for drug approval

The most crucial channel for ultimate commercialization is direct engagement with regulatory authorities. AIM ImmunoTech's teams are heavily focused on moving Ampligen toward eventual FDA approval for pancreatic cancer. While the focus is on the FDA pathway, the company also secured intellectual property channels in Europe, specifically being granted European Patent No. 4,096,675 covering Ampligen for use in treating Long COVID.

Furthermore, the company secured a patent in Japan covering Ampligen combined with checkpoint inhibitors that extends through the year 2039. These IP grants represent secured future market access channels.

• Ongoing focus on FDA approval pathway for pancreatic cancer.
• European Patent No. 4,096,675 granted for Long COVID compositions.
• Japanese patent secured for cancer therapy combination through 2039.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Customer Segments

You're mapping out the core customer base for AIM ImmunoTech Inc. (AIM) as of late 2025. This isn't a broad consumer play; it's highly specialized, focusing on patients with severe, unmet medical needs and strategic industry partners. The financial reality shows a company intensely focused on clinical execution, with a Q3 2025 net loss of $(3.3 million) and cash reserves of $2.4 million as of September 30, 2025. That cash position, against an expected monthly burn rate of approximately ~$550,000, means every patient segment and partnership is critical for runway extension.

Here's a breakdown of the distinct customer segments AIM ImmunoTech Inc. targets with its lead investigational drug, Ampligen (rintatolimod).

Patient Populations Targeted by Ampligen

The primary patient segments are defined by the indications where Ampligen shows potential, particularly in oncology and post-viral syndromes. The company's R&D spend for the three months ended September 30, 2025, was approximately $607,000, reflecting this clinical focus.

• Oncology patients with late-stage, difficult-to-treat cancers.
• Patients suffering from moderate-to-severe Post-COVID fatigue and ME/CFS.

For the ME/CFS and Long COVID segment, the urgency is clear. The prevalence of patients meeting the 2015 Institute of Medicine ME/CFS clinical diagnostic criteria is reported as five times higher than pre-pandemic estimates. Furthermore, data from the NIH RECOVER initiative showed that among participants infected with SARS-CoV-2, the incidence of ME/CFS was 15 times higher than pre-pandemic rates.

The clinical data from the AMP-518 trial specifically points to a target subgroup within this patient base. Here's the quick math on the 6MWT (Six-Minute Walk Test) improvement for Long COVID patients in that study:

Patient Subgroup	Mean 6MWT Improvement (Meters)	Placebo Mean Improvement (Meters)	Statistical Significance
Baseline 6MWT < 205 meters	139	91	p<0.02

In oncology, AIM ImmunoTech Inc. is heavily focused on pancreatic cancer, which CEO Thomas K. Equels noted as one of the most aggressive and difficult-to-treat cancers. The company is also advancing data from studies in advanced recurrent ovarian cancer and triple-negative breast cancer (TNBC).

Strategic and Institutional Customers

Beyond direct patient treatment, a significant part of AIM ImmunoTech Inc.'s business model involves engaging with larger entities for development, funding, and potential acquisition. These entities represent future revenue streams through licensing or collaboration milestones.

• Large pharmaceutical companies seeking to license or acquire immuno-oncology assets.
• Government and non-profit organizations funding medical research (e.g., NCI).

AIM ImmunoTech Inc. is actively pursuing these relationships. For instance, the development of Ampligen in pancreatic cancer is a collaboration with AstraZeneca in the ongoing DURIPANC Phase 2 trial. They also noted a collaboration with Merck for an advanced ovarian cancer trial. The company explicitly states it is highly interested in collaborative opportunities including product out-licensing, co-research, co-development, co-promotion, and co-marketing with pharmaceutical companies domestically and internationally. Furthermore, the company highlighted discussions on private-public partnerships at the U.S.-Poland Science and Technology Symposium 2025, signaling engagement with institutional and governmental bodies.

The financial structure of Q3 2025 shows General and Administrative expenses at approximately $1.8 million, which covers the overhead to manage these complex relationships. The company's stated interest in securing the successful future of Ampligen suggests that securing a major partnership or licensing deal is a key near-term objective to de-risk the current cash position.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for AIM ImmunoTech Inc. as of late 2025. The cost structure is heavily weighted toward advancing the clinical pipeline, which is typical for a clinical-stage biopharma company.

The most significant operational outlays are concentrated in research and development and general overhead. Here's a look at the key figures from the third quarter of 2025.

Expense Category	Q3 2025 Amount	Comparison to Q3 2024
Research and Development (R&D) Expense	$607,000	Decreased from $1.4 million
General and Administrative (G&A) Expense	$1.8 million	Decreased from $3.1 million
Net Loss from Operations	$(3.3 million)	Improved from $(3.7 million)

The R&D spend reflects the ongoing commitment to clinical execution, particularly for the Ampligen pancreatic cancer program. The G&A figure covers the necessary infrastructure to support these efforts.

The operational cash consumption is a critical metric for runway planning. Management reports the expected monthly cash burn rate for operations:

• Monthly cash burn rate for operations: approximately ~$550,000.

Beyond the headline quarterly numbers, the cost structure includes several high-fixed or recurring elements essential for maintaining the company's asset base and compliance.

• Costs associated with running and monitoring multi-site clinical trials, such as the DURIPANC trial.
• Legal and patent maintenance costs covering the global Intellectual Property portfolio, including a Japanese patent through 2039.
• Costs related to regulatory filings and compliance, following the SEC extension filing on November 17, 2025.

Finance: draft 13-week cash view by Friday.

AIM ImmunoTech Inc. (AIM) - Canvas Business Model: Revenue Streams

You're looking at the current cash inflows for AIM ImmunoTech Inc., and honestly, the picture is one of heavy reliance on capital markets rather than product sales right now. The core operational revenue stream remains minimal, as you'd expect for a clinical-stage biotech. For the third quarter ending September 30, 2025, the reported total revenue was just $26,000. This compares to $35,000 in the prior year's third quarter.

The most significant recent cash event was the equity financing. AIM ImmunoTech closed a public offering in July 2025, bringing in gross proceeds of $8.0 million. This capital is essential to keep the lights on and fund the ongoing clinical work, though it came with significant dilution risks due to the issuance of shares and accompanying warrants.

Here's a quick look at the recent capital activity that feeds the top line, even if it isn't traditional sales revenue:

Funding Source/Event	Amount Reported	Date/Period
Q3 2025 Total Revenue	$26,000	Three Months Ended September 30, 2025
Gross Proceeds from July 2025 Equity Offering	$8.0 million	July 2025
Nine Months 2025 Total Revenue	$67,000 (USD 0.067 million)	Nine Months Ended September 30, 2025

A key component of the funding structure involves non-dilutive support from institutional partners, which helps offset AIM ImmunoTech's internal research and development spending. This is money that doesn't require issuing new stock, which is a big plus for existing shareholders.

• The DURIPANC trial for pancreatic cancer is funded through a collaboration involving AstraZeneca and Erasmus Medical Center.
• The Refractory Melanoma Phase 2 study has grant funding from the National Cancer Institute.
• The Stage 4 Triple Negative Breast Cancer Phase 1/2a study is grant funded by both Merck and the National Cancer Institute.
• The Advanced Recurrent Ovarian Cancer Phase 2 study is grant funded by Merck.

As for future revenue, you must look at the potential from Ampligen's clinical success. Currently, sales revenue from Ampligen is zero, as it remains an investigational drug pending regulatory approval. However, the July 2025 financing structure included warrants that could potentially bring in an additional $16 million if exercised. Furthermore, the company has an existing approval for Ampligen in the Argentine Republic for severe Chronic Fatigue Syndrome, though the associated revenue stream isn't detailed as a current major contributor. Milestone payments and upfront fees from any licensing agreements are potential future inflows, but no specific amounts are reported as realized for late 2025.